Article
Gavreto, FDA Approved for Treatment of Metastatic RET Fusion-Positive NSCLC, Available at Biologics by McKesson
Gavreto was granted accelerated approval by the FDA on September 4, 2020, for the treatment of adult patients with metastatic RET fusion-positive non–small cell lung cancer (NSCLC).
CARY, N.C.—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Blueprint Medicines as a specialty pharmacy provider for Gavreto (pralsetinib) for the treatment of adult patients with metastatic RET fusion-positive non–small cell lung cancer (NSCLC) as detected by an FDA-approved test.
Gavreto, which was granted accelerated approval by the FDA on September 4, 2020, was specifically designed to inhibit RET alterations. RET fusions are oncogenic drivers for multiple solid tumor types. This drug was given priority review by the FDA, which is granted to drugs that are expected to have a large impact on a disease’s treatment.
“Gavreto gives patients a new RET inhibitor option for treating their RET-driven metastatic NSCLC,” said Allison Kinnarney, director of Clinical Programs with Biologics.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
